Overview
Attentional Mechanisms in SCD
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2028-06-30
2028-06-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.Phase:
Early Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Vanderbilt University Medical CenterTreatments:
Mecamylamine
Criteria
Inclusion Criteria:1. age ≥ 55
2. Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating
< 3
3. Non-smokers
Exclusion Criteria:
1. medical contraindications to the drug challenge
2. primary neurological disorder (such as stroke, epilepsy, etc.)